Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

abine for five days.

Preliminary data for this trial were previously announced at the American Society of Hematology Annual Meeting in December 2007.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , NEW YORK, Dec. 2 Reportl...ort is available in its catalogue: ,, EEG/EMG... ,, http://www.reportlinker.com/p0164319/EEG/...ds.html ,, Steep rise in obesity, cardiovascul...Electroencephalograph (EEG) diagnostic and monitor...
(Date:12/2/2009)... , FRAZER, Pa., Dec. 2 /PRNewswire-FirstCall...ed that it has filed a lawsuit in U.S. District Co...Inc. for infringement of U.S. Patent Nos. 7,132,57...") and RE37,516 (the ",516 Patent") for the Cephal...IV]. Cephalon has a three-year period of marketin...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Pharma...ends ,, http://www.reportlinker.com/p016424...arket-Trends.html ,, Global pharma industry ...g competition in generic markets, rising cost of n...
Breaking Medicine Technology:Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 2Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 3Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 4Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 5Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 6Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 7Reportlinker Adds EEG/EMG/Brain Function Monitoring - Global Market Trends 8Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 1New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 1Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 3Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 4Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 5Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 7Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 8CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 1CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 2
...t Reproductive Medicine Associates, of New Jersey ...ciety for Reproductive Medicine A...ct. 18 Researchers at,Reproductive Medicine Assoc...rd for research at the American Society for Reprod...nology making it possible to provide accurate,rapi...
...enable specific cells in the,retina to multiply an...rate,genetic manipulations might coax an injured b...nvestigators at St.,Jude Children,s Research Hospi...e eye cancer retinoblastoma, disproving a long-sta...he finding suggests for the first time that,it may...
Other Medicine Technology:Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 2Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 3St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3
(Date:12/2/2009)... 2 In response to a pr...afety Now ," an initiative from the U.S. Anti-Do...ouncil for Responsible Nutrition (CRN), the leadin...ement industry, issued the following statement: ,... CEO: ,, "We share the concerns of Travis Tyg...
(Date:12/2/2009)...vanced cases, study finds , , WEDNESDAY,...s, survival rates for advanced lung cancer patient...ew study has found. , Researchers analyzed data...e 4 non-small cell lung cancer (NSCLC) between 199.... National Cancer Institute,s Surveillance, Epidem...
(Date:12/2/2009)...e remains unclear, researchers say , , W...suggests that enzyme replacement therapy can make ...ry disease, a rare illness that affects the kidney... linked to the lack of an enzyme that helps metabo...cause it boosts the risk for a stroke, heart attac...
(Date:12/2/2009)...., Dec. 2 Researchers f...n blood cancer research at the annual American Soc... December 4-8, 2009. ,, Throughout the ASH con... experts, including Chief Medical Officer Barton K...t Services Hildy Dillon, and Vice President, Resea...
(Date:12/2/2009)... federal government ends nine months of obstructio...Newswire-USNewswire/ -- More than 2,300 healthcare...lities across Southern California will soon vote o...ealthcare Workers (NUHW). ,, A majority of the ...but SEIU delayed the election by filing frivolous ...
Breaking Medicine News(10 mins):Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Gains Made in Lung Cancer Survival 2Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2
...N, Feb. 28 Montana Governor Brian Schweitzer (Cha...ryland Governor Martin O,Malley (Vice Chair of the...election of former DGA Chair Gov. Kathleen Sebeliu...e effort to fix it," Governor Schweitzer said. "In...
... CheckOrphan, the leading news site... iWish, which allows people to visually (creative,...ion of these diseases through and image. In additi...n general. , Basel, Switz...
...GAS, NV New research presented at the 2009 Americ...y Day in Las Vegas suggests that elbow ulnar colla...tion in the Major League Baseball (MLB) draft does...es who had undergone UCL reconstruction prior to t...
...atient Communication Service introduces vSling for...n the web. , , LEHI, Utah, Feb. 27 Smile Reminde...communication feature, vSling, at The 144th Chicag... Reminder to show its revenue boosting communicati...
... is one result, and experts urge better awareness ...HealthDay News) -- Snowblowers might make clearing...e them continue to show up in emergency rooms with...n be reconstructed," said Dr. Daniel Master, an or...
...-Vision Stockholders to Vote GOLD , , CINCINNATI,...ces that Glass Lewis & Co., LLC, a leading ind...ecommended that LCA-Vision stockholders vote to re...ent Directors, in the Joffe Group,s consent solici...
Other Medicine News:Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3Health News:Elbow ligament reconstruction appears not to effect future professional advancement in baseball 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 3Health News:Snowblower Hand Injuries Often Extensive, Study Finds 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 4
Assistant Free™ Stulberg Leg Positioner
KneeGrip™
autoLog™ Autotransfusion System
...etics OrthoPAT system collects and cleanses red bl... the first product of its kind designed specifical...od loss of orthopedic surgical patients. The syste...nd an electromechanical device which together coll...
Medicine Products: